A PhIII Tecentriq win? Not so much, it turns out, as Roche spells out weak data on bladder cancer
When Roche first top-lined their IMvigor130 study a couple of months ago, company execs called it the “first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer.” The study, they said in trumpeting the success, hit the co-primary on progression-free survival.
But they were being kind to themselves.
Over the weekend at ESMO its own investigators said they don’t believe they could likely gain an approval with the data in Tecentri combined with chemo — which are weak.
Investigator Ignacio Durán “cautioned that this improvement in progression free survival may be insufficient for regulatory approval at this stage, but said the data look promising,” reads ESMO’s statement on the data.
Hardly a ringing endorsement.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.